2615.8000 -17.10 (-0.65%)
NSE Nov 17, 2026 15:31 PM
Volume: 292.7K
 

Motilal Oswal
Glenmark Pharma (GNP) posted a marginally lower-than-expected operating performance in 4QFY25 (2%/5% miss on revenue/EBITDA). Elevated interest outgo and lower other income led to a 16% miss on earnings.
Glenmark Pharma has gained 37.99% in the last 1 Year
More from Glenmark Pharmaceuticals Ltd.
Recommended